Skip to main content
Premium Trial:

Request an Annual Quote

Microarray-Manufacturer Febit in Insolvency Proceedings in Germany

NEW YORK, Oct. 8 (GenomeWeb News) - Germany's Febit has gone out of business, just months after launching its first product, the Geniom One DNA analysis instrument, GenomeWeb has learned.

The Mannheim-based company filed for insolvency earlier in the year and proceedings were opened July 1. Creditors met with Febit's insolvency lawyer, Christopher Seagon, on Aug. 16. Seagon, who maintains offices in Heidelberg, was unavailable for comment on the proceedings.

Febit, which was founded in 1998, raised €30 million ($37 million) in a third round of private financing in late 2002. Among its investors are the EMBL Technology Fund and Infineon Ventures, neither of which responded to e-mails seeking comment.

Geniom One was launched late last year, and according to the firm, could synthesize custom oligo arrays, perform experiments, and scan arrays all within the confines of the instrument. It had promised to launch the product by the end of 2002, but efforts to work out the bugs delayed the product's introduction by a year.

The Scan

Study Reveals Details of SARS-CoV-2 Spread Across Brazil

A genomic analysis in Nature Microbiology explores how SARS-CoV-2 spread into, across, and from Brazil.

New Study Highlights Utility of Mutation Testing in Anaplastic Thyroid Cancer

Genetic mutations in BRAF and RAS are associated with patient outcomes in anaplastic thyroid carcinoma, a new JCO Precision Oncology study reports.

Study Points to Increased Risk of Dangerous Blood Clots in COVID-19 Patients

An analysis in JAMA Internal Medicine finds that even mild COVID-19 increases risk of venous thromboembolism.

Y Chromosome Study Reveals Details on Timing of Human Settlement in Americas

A Y chromosome-based analysis suggests South America may have first been settled more than 18,000 years ago, according to a new PLOS One study.